Journey into muscular dystrophies caused by abnormal glycosylation

Acta Myologica

Volumn 23, Issue 2, 2004, Pages 79-84

  Muntoni, Francesco ^a,b  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alpha dystroglycan; Glycoslyation; Glycosyltransferases; Muscular dystrophy; Neuronal migration

Indexed keywords

DYSTROGLYCAN; DYSTROPHIN; GLYCOPROTEIN; GLYCOSYLTRANSFERASE;

BRAIN DISEASE; CELL MIGRATION; CLINICAL FEATURE; DISEASE SEVERITY; EYE DISEASE; FUKUTIN GENE; FUKUYAMA CONGENITAL MUSCULAR DYSTROPHY; FXRP GENE; GENE; GENE MUTATION; GNE GENE; HUMAN; INCLUSION BODY MYOSITIS; LARGE GENE; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE EYE BRAIN DISEASE; MUSCULAR DYSTROPHY; NERVE CELL; NONHUMAN; POMGNT1 GENE; POMT1 GENE; PROTEIN GLYCOSYLATION; REVIEW; WALKER WARBURG SYNDROME;

DNA MUTATIONAL ANALYSIS; DYSTROGLYCANS; GENOTYPE; GLYCOGEN; GLYCOSYLATION; GLYCOSYLTRANSFERASES; HUMANS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; PHENOTYPE;

EID: 9344239893     PISSN: 11282460     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Muntoni F, Brockington, M., Torelli, S, et al. Defective glycosylation on congenital muscular dystrophies. Cuff Opin Neurol 2004;17:205-9.
2. Martin PT. Glycobiology of the neuromuscular junction. J Neurocytol 2003;32:915-29.
3. Michele DE, Campbell KP. Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. J Biol Chem 2003;278:15457-60.
4. Montanaro F, Carbonetto S. Targeting dystroglycan in the brain. Neuron 2003;37:193-6.
5. Endo T, Toda T. Glycosylation. in congenital muscular dystrophies. Biol Pharm Bull 2003;26:1641-7.
6. Hewitt JE, Grewal PK. Glycosylation defects in inherited muscle disease. Cell Mol Life SO 2003;60:251-8.
7. Endo T. O-mannosyl glycans in mammals. Biochim Biophys, Acta 1999;1473:237-46.
8. Muntoni F, Brockington M, Torelli S, et al. Defective glycosylation in congenital muscular dystrophies. Curr Opin Neurol 2004;17:205-9.
9. Martin PT. Dystroglycan glycosylation and its role in matrix binding in skeletal muscle. Glycobiology 2003;13:55R-66R.
10. Henry MD, Campbell KP. Dystroglycan inside and out. Curr Opin Cell Biol 1999;11:602-7.
11. Ervasti SM, Campbell KP. Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. Mol Cell Biol Hum Dis Ser 1993;3:13966.
12. Michele DE, Barresi R, Kanagawa. M, et al. Post-translational disruption of dystroglycanligand interactions in congenital muscular dystrophies. Nature 2002;418:417-22.
13. Brown SC, Torelli S, Brockington M, et al. Abnormalities in alpha-dystroglycan expression in MDC1C and LGMD21 muscular dystrophies. Am J Pathol 2004;164:72737.
14. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. Hum Mol Genet 2003;2853-61.
15. Dobyns WB, Pagon RA, Armstrong D, et al. Diagnostic criteria for Walker-Warburg syndrome. Am J Med Genet 1989;32:195-10.
16. Moore SA, Saito F, Chen J, et al. Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature 2002;418:422-5.
17. Beltran-Valero de Bernabe D, Currier S, Steinbrecher A, et al. Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. Am J Hwn Genet 2002;71:1033-43.
18. Muntoni F, Valero de Bernabe B, Bittner R, et at. 114th ENMC International Workshop on Congenital Muscular Dystrophy (CMD) 17-19 January 2003, Naarden, The Netherlands (8th Workshop of the International Consortium on CMD; 3rd Workshop of the MYOCLUSTER project GENRE). Neuromuscul Disord 2003;13:579-88.
19. Willer T, Valero MC, Tanner W, et al. O-mannosyl glycans: from yeast to novel associations with human disease. Curr Opin Struct Biol 2003;13:621-30.
20. Manya H, Chiba A, Yoshida A, et al. Demonstration of mammalian protein O-mannosyltransferase activity: coexpression of POMT1 and POMT2 required for enzymatic activity. Proc Nat Acad Sci USA 2004;101:500-5.
21. Jimenez-Mallebrera C, Torelli S, Brown SC, et al, Profound skeletal muscle depletion of alpha-dystroglycan in Walker-Warburg syndrome. Eur J Paediatr Neurol 2003;7:129-37.
22. Cormand B, Pihko H, Bayes M, et al. Clinical and genetic distinction between WalkerWarburg syndrome and muscle-eye-brain disease. Neurology 2001;56:1059-69.
23. Cormand B, Avela K, Pihko H, et al. Assignment of the muscle-eye-brain disease gene to 1p32-p34 by linkage analysis and homozygosity mapping. Am J Hum Genet 1999;64:126-35.
24. Pihko H, Lappi M, Raitta C, et al. Ocular findings in muscle-eye-brain (MEB) disease: a follow-up study. Brain Dev 1995;17:57-61.
25. Taniguchi K, Kobayashi K, Saito K, et al. Worldwide distribution and broader clinical spectrum of muscle-eye-brain disease. Hum Mol Genet 2003;12:527-34.
26. Yoshida A, Kobayashi K, Manya H, et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev Cell 2001;1:717-24.
27. Manya H, Sakai K, Kobayashi K, et al. Loss-of function of an N-acetylglucosaminyltransferase, POMGnT1, in muscle-eye-brain disease. Biochem Biophys Res Commun 2003;306:93-7.
28. Zhang W, Vajsar J, Cao P, et al. Enzymatic diagnostic test for Muscle-Eye-Brain type congenital muscular dystrophy using commercially available reagents. Clin Biochem 2003;36:339-44.
29. Osawa M, Arai Y, Ikenaka H, et al. Fukuyama type congenital progressive muscular dystrophy. Acta Paediatr Jpn 1991;33:261-9.
30. Toda T, Kobayashi K, Takeda S, et al. Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. Congenit Anom Kyoto 2003;43:97-104.
31. Yoshioka M, Kuroki S. Clinical spectrum and genetic studies of Fukuyama congenital muscular dystrophy. Am J Med Genet 1994;53:245-50.
32. Toda T, Miyake M, Kobayashi K, et al. Linkage-disequilibrium mapping narrows the Fukuyama-type congenital muscular dystrophy (FCMD) candidate region to < 100 kb. Am J Hum Genet 1996;59:1313-20.
33. Silan F, Yoshioka M, Kobayashi K, et al. A new mutation of the fukutin gene in a non-Japanese patient. Ann Neurol 2003;53:392-6.
34. de Bernabe DB, van Bokhoven H, van Beusekorn E, et al. A homozygous nonsense mutation in the fukutin gene causes a Walker-Warburg syndrome phenotype. J Med Genet 2003;40:845-8.
35. Muntoni F, Brockington M, Blake DJ, et al. Defective glycosylation in muscular dystrophy. Lancet 2002;360:1419-21.
36. Topaloglu H, Brockington M, Yuva Y, et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 2003;60:988-92.
37. Beltran-Valero de Bernabe D, Voit T, Longman C, et al. Mutations in the FKRP gene can cause muscle-eye-brain disease and Walker-Warburg syndrome. J Med Genet 2004;41:61.
38. Poppe M, Cree L, Bourke J, et al. The phenotype of limb-girdle muscular dystrophy type 21. Neurology 2003;60:1246-51.
39. Mercuri E, Brockington M, Straub V, et al. Phenotypic spectrum associated with mutations in the fakutin-related protein gene. Ann Neurol 2003;53:537-42.
40. Harel T, Goldberg Y, Shalev SA, et al. Limb-girdle muscular dystrophy 21: phenotypic variability within a large consanguineous Bedouin family associated with a novel FKRP mutation. Eur J Hum Genet 2004;12:38-43.
41. Paula Fd F, Vieira N, Starling A, et al. Asymptornatic carriers for homozygous novel mutations in the FKRP gene: the other end of the spectrum. Eur J Hum Genet 2003;11:923-30.
42. Holzfeind PJ, Grewal PK, Reitsarner HA, et al. Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation- deficient muscle-eye-brain disorders. Hum Mol Genet 2002;11:2673-87.
43. Longman C, Brockington M, Torelli S, et al. Mutations in the human LARGE gene cause MDC I D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of {alpha}-dystroglycan. Hum Mol Genet 2003;12:2853-61.
44. Eisenberg I, Avidan N, Potikha T, et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001;29:83-7.
45. Stasche R, Hinderlich S, Weise C, et al. A bifunctional enzyme catalyzes the first two steps in N-acetylneuraminic acid biosynthesis of rat liver. Molecular cloning and functional expression of UDP-N-acetyl-glucosamine 2-epimeraseN-acetylmannosamine kinase. J Biol Chem 1997;272:24319-24.
46. Huizing M, Rakocevic G, Sparks SE, et al. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol Genet Metab 2004;81:196-202.
47. Saito F, Tomimitsu H, Arai K, et al. A Japanese patient with distal myopathy with rimmed vacuoles: missense mutations in the epimerase domain of the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene accompanied by hyposialylation of skeletal muscle glycoproteins. Neuromuscul Disord 2004;14:158-61.
48. Noguchi S, Keira Y, Murayarna K, et al. Reduction of UDP-N- acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J Biol Chem 2004;279:11402-7.